Background: Participants in clinical trials often do not reflect the populations that could benefit from the treatments being investigated. There are known barriers to trial participation for under-served groups, but limited evidence on strategies to alleviate these barriers to improve representation. This scoping review aimed to identify effective interventions and design features that improve the representation `of under-served groups in trials, focusing on the UK and Ireland.
Methods: We included methodological research studies that reported interventions to improve representation of ethnic minority groups, socioeconomically disadvantaged groups, older people, or those with impaired capacity to consent to randomised controlled trials, conducted in the UK and Ireland, published between 2000-2021. Systematic searches were conducted in November 2021 and data were independently extracted by two authors and narratively synthesised.
Results: Seven studies were included: one randomised controlled study embedded in five trials, one mixed-methods study, and five studies reporting 'lessons learnt' from one trial. We categorised the 47 reported interventions or strategies into nine broad themes: Recruitment sites, recruitment settings, community engagement, and communication with participants, incentives, inclusion criteria, flexibility, patient documentation, and the consent process. Only 28/47 interventions were evaluated, 23 of which were comparison of recruitment pathways.The randomised study found that a £100 incentive mentioned in the invitation letter increased positive responses overall across drug trials in cardiovascular disease and hypertension, but not for older people or those living in the most deprived areas. Invitation letters via GPs and working with communities were reported as successful recruitment pathways in recruiting different under-served populations.
Conclusions: Interventions aiming to improve the recruitment of under-served groups in the UK and Ireland were reported across seven papers, but their effectiveness was rarely rigorously evaluated. Included studies were context specific. Using a variety of recruitment methods is likely to help achieve a more diverse cohort.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11408910 | PMC |
http://dx.doi.org/10.3310/nihropenres.13524.1 | DOI Listing |
Br J Nutr
January 2025
Department of Food Studies, Nutrition and Dietetics, Uppsala University, 753 10 Uppsala, Sweden.
Low vegetable consumption among school-age children and adolescents put them at risk of micronutrient malnutrition and non-communicable diseases. There is a dearth of synthesized literature on vegetable intake and interventions to promote increased consumption among this age-group in West-Africa. This study pooled evidence on vegetable consumption and interventions to promote vegetable consumption among school- age children and adolescents (6-19 years) in West-Africa.
View Article and Find Full Text PDFJBI Evid Synth
January 2025
School of Nursing, Faculty of Health, Dalhousie University, Halifax, NS, Canada.
Objective: The objective of this review is to identify international and Nova Scotian standards of care, CPGs, and policies informing equitable health care.
Introduction: The lack of attention given to intersectional health care needs of diverse populations perpetuates health inequities among under-served groups, creating an urgent need for health care reform globally.
Inclusion Criteria: This scoping review will include standards of care, CPGs, and policies focusing on equity-related health indicators.
Health Expect
December 2024
NIHR Health Protection Research Unit in Behavioural Science and Evaluation, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Introduction: There are many recognised benefits of public involvement, including more relevant research. The COVID-19 pandemic highlighted the existing health inequalities and disparities in access to care and treatment for under-served groups, necessitating meaningful and sustainable approaches to engaging them in health research. However, there is limited guidance to suggest what groundwork and processes are necessary for initiating such projects.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Enigma Biomedical Group, Knoxville, Tennessee, USA.
The revised biomarker framework for diagnosis and staging of Alzheimer's disease (AD) relies on amyloid beta (Aβ) and tau pathologies as core markers, and markers for adjacent pathophysiology, such as neurodegeneration and inflammation. Many of the core fluid biomarkers are phosphorylated tau (p-tau) fragments, with p-tau217 showing a prominent association with Aβ and tau. While positron emission tomography (PET) imaging is well established, plasma p-tau assays are newer and likely to reduce the use of expensive, and less accessible cerebrospinal fluid and PET imaging tests, thereby promoting wider access to AD screening.
View Article and Find Full Text PDFTrials
November 2024
COUCH Health, Manchester, UK.
Background: The benefits of randomised trials are not shared equally, and people from ethnic minority groups are a key constituency under-served by clinical research and clinical care. The STRIDE project aimed to give trialists practical information about how to decide which ethnic groups should be in their trials, and at what proportion.
Methods: We considered trials in six clinical areas: cancer, cardiovascular, diabetes, maternal health, mental health, and smoking cessation.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!